TPJG Health Tracker

Current Lab Order — March 10, 2026

Ordered by Dr. Maya J. Halliburton at Gordon Crofoot MD PA. Results expected by Monday, March 16, 2026.

Test	Code	ICD-10 Dx	Interpretation
Prot+CreatU (Random)	003129	N39.8	Urine protein & creatinine ratio — kidney function screening
Testosterone, Serum	004226	E34.9	Endocrine monitoring — testosterone level assessment
CBC With Differential/Platelet	005009	E34.9	Complete blood count — overall blood health
HbA1c with eAG Estimation	102525	E11.8	3-month blood sugar average — TYPE 2 DIABETES
Lipid Panel	303756	Z13.220	Cholesterol screening — cardiovascular risk assessment
Comprehensive Metabolic Panel (14)	322000	E34.9	Organ function baseline — liver, kidney, electrolytes, glucose

What to Watch For

When results arrive, key numbers to compare against historical trends: HbA1c (target <6.5%, ideal <5.7%), Fasting Glucose (target <100), Testosterone (on/off TRT context), HDL (target >40), LDL (target <100).

Most Recent Lab Snapshot — October 12, 2023

6.2%

HbA1c

Ref: 4.2–5.6%

145

Glucose

Ref: 70–99 mg/dL

1,357

Testosterone

On TRT • Ref: 300–890

30

HDL

Ref: >39 mg/dL

133

LDL

Ref: <100 mg/dL

17

Insulin

Ref: 2–21 UIU/mL

27

Vitamin D

Ref: 30–100 ng/mL

51.3%

Hematocrit

Ref: 40–51% (TRT effect)

Diabetes & Metabolic Trends

Primary concern: Type 2 Diabetes confirmed December 2025. Currently on Metformin + Signos CGM. Goal: regain insulin sensitivity.

HbA1c Trend (3-Month Blood Sugar Average)

Date	HbA1c	Status	Provider	Trend
Feb 2019	5.5%	NORMAL	NBH — Dr. Szelei-Stevens	—
Dec 2018	6.0%	PREDIABETIC	NBH — Dr. Szelei-Stevens	↑ +0.5
Aug 2021	6.1%	PREDIABETIC	NBH — Dr. Jackson	↑ +0.1
May 2022	6.2%	DIABETIC RANGE	NBH — Dr. Jackson	↑ +0.1
Oct 2023	6.2%	DIABETIC RANGE	NBH/CPL — Dr. Jackson	→ 0.0
Mar 2026	Pending	ORDERED	Crofoot — Dr. Halliburton	—

Fasting Glucose Trend

Date	Glucose (mg/dL)	Ref: 70–99	Trend
Dec 2018	94	NORMAL	—
Aug 2021	99	BORDERLINE	↑ +5
May 2022	111	HIGH	↑ +12
Oct 2023	145	HIGH	↑ +34
Mar 2026	Pending (CMP)	ORDERED	—

Fasting Insulin Trend (Insulin Resistance Marker)

Date	Insulin (UIU/mL)	Ref: 2–21	HOMA-IR Est.	Trend
Feb 2019	8	NORMAL	~1.0 (optimal)	—
Aug 2021	12	RISING	~2.9 (borderline)	↑ +4
May 2022	13	RISING	~3.6 (resistant)	↑ +1
Dec 2018	16	ELEVATED	~3.7 (resistant)	↑ +3
Oct 2023	17	HIGH-NORMAL	~6.1 (resistant)	↑ +1

Critical Pattern: Progressive Insulin Resistance

Insulin has more than doubled from 8 (2019) to 17 (2023) while remaining within “normal” lab range. This is the classic Type 2 progression: the body produces more insulin to compensate for resistance, glucose still rises. HOMA-IR >2.5 indicates insulin resistance. By Oct 2023, estimated HOMA-IR was ~6.1 — well into resistant territory.

Current interventions: Metformin (daily), Signos CGM (switched from Stelo Jan 2026), health coach Jamie exploring GLP-1/peptide options.

Testosterone & Hormone Trends

History of BioTE testosterone pellet therapy through Natural Bio Health-Houston. Levels fluctuate dramatically based on TRT status.

Total Testosterone Trend

Date	Testosterone (ng/dL)	Ref: 300–890	TRT Status	Provider
Jul 2017	1,237	HIGH (on TRT)	Post-Pellet Profile	NBH — Dr. Szelei-Stevens
Nov 2017	642	NORMAL	Follow-up (waning)	NBH — Dr. Szelei-Stevens
Dec 2018	656	NORMAL	Off / Between cycles	NBH — Dr. Szelei-Stevens
Feb 2019	1,550	HIGH (on TRT)	On pellets	NBH — Dr. Szelei-Stevens
Jul 2019	916	SLIGHTLY HIGH	On pellets (waning)	NBH — Dr. Szelei-Stevens
Aug 2021	447	NORMAL	Off TRT	NBH — Dr. Jackson
May 2022	1,372	HIGH (on TRT)	On pellets	NBH — Dr. Jackson
Oct 2023	1,357	HIGH (on TRT)	On pellets	NBH/CPL — Dr. Jackson
Mar 2026	Pending	ORDERED	Unknown	Crofoot — Dr. Halliburton

Free Testosterone & SHBG

Date	Free T (pg/mL)	Ref: 47–244	SHBG (nmol/L)	Ref: 19.3–76.4
Jul 2017	21.3*	diff ref range	60.3	NORMAL
Nov 2017	13.4*	diff ref range	35.9	NORMAL
Dec 2018	78.9	NORMAL	76.1	BORDERLINE
Feb 2019	224.3	NORMAL	81.2	HIGH
Jul 2019	134.9	NORMAL	65.3	NORMAL
Aug 2021	76.1	NORMAL	—	—
May 2022	279.2	HIGH	50.6	NORMAL
Oct 2023	289.4	HIGH	47.0	NORMAL

Gonadotropins & Related Hormones

Date	FSH (IU/L)	LH (IU/L)	DHEA-S (ug/dL)	Estradiol (pg/mL)
Feb 2019	—	—	83	—
May 2022	<0.3 L	—	—	—
Oct 2023	<0.3 L	<0.3 L	323 H	59.1

TRT Impact: Hypothalamic-Pituitary Suppression

FSH and LH are fully suppressed (<0.3) when on testosterone therapy — this is expected. The body’s natural production shuts down when exogenous testosterone is present. DHEA-S at 323 (high) in Oct 2023 may indicate adrenal overcompensation. Hematocrit elevation (51.3%) is a known TRT side effect requiring monitoring.

Cardiovascular & Lipid Trends

Lipid Panel History

Date	Total Chol	LDL	HDL	Triglyc	Risk Ratio
Dec 2018	174	117 H	37 L	98	3.17
Aug 2021	236 H	170 H	42	115	—
May 2022	184	136 H	33 L	61	—
Oct 2023	182	133 H	30 L	89	—
Mar 2026	Pending	Pending	Pending	Pending	—

Critical: HDL Declining — Now Below Safe Threshold

HDL has dropped steadily: 42 → 37 → 33 → 30. An HDL below 40 mg/dL in men is considered a major cardiovascular risk factor. At 30, this is seriously low. LDL remains consistently elevated above 100. Combined with Type 2 diabetes, this creates a compounded cardiovascular risk profile.

Inflammation Markers

Date	hsCRP (mg/L)	Risk Level	Homocysteine (umol/L)	Ref: <12
Dec 2018	1.3	AVERAGE	13 H	ELEVATED
Feb 2019	—	—	12 H	BORDERLINE
Jul 2019	—	—	14 H	HIGH
Aug 2021	0.9	LOW	10	NORMAL
May 2022	—	—	13 H	ELEVATED
Oct 2023	1.2	AVERAGE	10	NORMAL

Vitamin D & Nutrient Trends

Vitamin D, 25-OH

Date	Vitamin D (ng/mL)	Status	Trend
Feb 2019	18	INSUFFICIENT (<20)	—
Jul 2019	24	SUBOPTIMAL (20–29)	↑ +6
Aug 2021	28	SUBOPTIMAL (20–29)	↑ +4
May 2022	62	OPTIMAL (30–100)	↑ +34
Oct 2023	27	SUBOPTIMAL (20–29)	↓ -35

Vitamin D: Supplementation Lapsed

Vitamin D reached optimal levels (62 ng/mL) in May 2022, likely with active supplementation. By Oct 2023 it crashed back to 27 — suggesting supplementation was discontinued. Vitamin D deficiency worsens insulin resistance, immune function, and bone density. Recommendation: Resume 5,000 IU daily D3 with K2.

Other Markers

Date	Ferritin (ng/mL)	ALT (U/L)	Hematocrit (%)	PSA (ng/mL)
Dec 2018	369	48	45.9	0.83
Aug 2021	511 H	62 H	—	—
May 2022	372	45	—	—
Oct 2023	241	48	51.3 H	0.93

Ferritin normalizing trend (511 → 241). ALT fluctuating near upper limit (liver function). Hematocrit elevated on TRT — requires monitoring for polycythemia risk. PSA stable and low (<1.0).

Complete Lab History — All Key Markers

Marker	Ref Range	Jul 17	Nov 17	Dec 18	Feb 19	Jul 19	Aug 21	May 22	Oct 23	Mar 26
HbA1c (%)	4.2–5.6	—	—	6.0	5.5	—	6.1	6.2	6.2	?
Glucose (mg/dL)	70–99	—	—	94	—	—	99	111	145	?
Insulin (UIU/mL)	2–21	—	—	16	8	—	12	13	17	—
Testosterone (ng/dL)	300–890	1237	642	656	1550	916	447	1372	1357	?
Free T (pg/mL)	47–244	21.3*	13.4*	78.9	224.3	134.9	76.1	279.2	289.4	—
Vitamin D (ng/mL)	30–100	—	—	—	18	24	28	62	27	—
Total Cholesterol	<200	—	—	174	—	—	236	184	182	?
LDL (mg/dL)	<100	—	—	117	—	—	170	136	133	?
HDL (mg/dL)	>39	—	—	37	—	—	42	33	30	?
Triglycerides	<150	—	—	98	—	—	115	61	89	?
Homocysteine	<12	—	—	13	12	14	10	13	10	—
hsCRP (mg/L)	<1.0 low	—	—	1.3	—	—	0.9	—	1.2	—
Ferritin (ng/mL)	30–400	—	—	369	—	—	511	372	241	—
ALT (U/L)	5–50	—	—	48	—	—	62	45	48	—
Hematocrit (%)	37–49/51	45.5	—	45.9	—	49.6	—	—	51.3	?

* Jul/Nov 2017 Free T used different reference range (4.8–25.7 ng/dL). Red = above range. Blue = below range. Green = normal. Purple = pending Mar 2026 results.

Key Findings & Suggestions

1. Insulin Resistance is the Root Issue

The data tells a clear story: insulin went from 8 (2019, optimal) to 17 (2023, resistant). Meanwhile HbA1c crept from 5.5% to 6.2% and glucose from 94 to 145. This is textbook progressive insulin resistance leading to Type 2 diabetes.

Continue Metformin — first-line therapy for insulin sensitization
Discuss GLP-1 agonist with Dr. Halliburton — Jamie recommended this approach; GLP-1s (Ozempic, Mounjaro) have strong evidence for reversing insulin resistance
Track with Signos CGM — real-time glucose data enables dietary adjustments
Target for Mar 2026 labs: HbA1c <6.0% would show meaningful improvement

2. HDL Critically Low — Cardiovascular Priority

HDL has declined from 42 to 30 over 5 years. Below 40 is a recognized independent risk factor. Combined with LDL >130 and diabetes, this significantly elevates heart disease risk.

Exercise is the most effective HDL booster — 30 min cardio 5x/week can raise HDL 5–10%
Omega-3 fatty acids (fish oil 2–4g/day) support HDL and lower triglycerides
Niacin (Vitamin B3) can raise HDL 15–35% — discuss with physician
Moderate alcohol raises HDL but not recommended given metabolic profile
Target: HDL >40 (minimum), ideally >50

3. Vitamin D Supplementation Needs Consistency

Vitamin D reached 62 (optimal) in May 2022 with active supplementation, then crashed to 27 by Oct 2023. Vitamin D deficiency worsens insulin resistance and cardiovascular risk — both primary concerns.

Resume Vitamin D3 5,000 IU daily with K2 for absorption
Take with a fat-containing meal for maximum bioavailability
Retest in 3 months to confirm levels back above 50

4. TRT Monitoring: Hematocrit & Hormonal Suppression

Testosterone therapy drives hematocrit up (51.3% in Oct 2023, at upper limit). Values >54% increase clot risk. FSH/LH are fully suppressed — natural production is offline. If TRT is continued, regular CBC monitoring is essential.

Monitor hematocrit every 3–6 months (included in today’s CBC order)
Consider therapeutic phlebotomy if hematocrit exceeds 52%
Discuss TRT continuation with Dr. Halliburton vs. potential fertility impacts

5. Positive Trends to Build On

Ferritin normalizing: 511 (2021) → 241 (2023) — good trajectory
Liver function stable: ALT within range at 48 (2023) after spike to 62 (2021)
PSA excellent: 0.93 (well under 4.0) — low prostate cancer risk
Triglycerides well-controlled: consistently under 150
Proactive monitoring: regular quarterly labs since April 2024 through Crofoot
CGM adoption: Signos provides real-time glucose data for behavioral change

Provider History

2017 – 2019

Natural Bio Health-Houston — Dr. Kathleen Szelei-Stevens
BioTE testosterone pellet therapy, hormone optimization, full panels

2021 – 2023

Natural Bio Health-Houston — Dr. Sarah Jackson
Continued TRT management, metabolic monitoring, weight loss profile

2024 – Present

Gordon Crofoot MD PA — Dr. Maya J. Halliburton
Primary care, quarterly labs via LabCorp/eclinicalmail portal, diabetes management

Dec 2025 – Present

Health Coach: Jamie (jlbburg22@aol.com)
Nutrition, GLP-1 planning, insulin sensitivity restoration. Also managing Keri’s iron absorption.

Current Medications & Devices

Item	Type	Purpose	Since
Metformin	Medication (daily)	Insulin sensitizer — first-line T2D	~2025
Signos CGM	Device (continuous)	Real-time glucose monitoring	Jan 2026 (switched from Stelo/Dexcom)
BioTE Testosterone Pellets	Hormone therapy	Testosterone replacement	~2017 (intermittent)
GLP-1 Agonist	Under discussion	Insulin resistance reversal	Pending — per Jamie’s recommendation

March 2026 Results — Awaiting

Results Expected: Monday, March 16, 2026

This section will be updated when results arrive. Key comparisons to make:

Marker	Oct 2023	Target	Mar 2026	Direction Needed
HbA1c	6.2%	<6.0%	—	Needs to drop (Metformin + diet impact)
Glucose	145	<100	—	Needs significant drop
HDL	30	>40	—	Needs to rise
LDL	133	<100	—	Needs to drop
Testosterone	1,357	300–890	—	Context-dependent (TRT status)
Hematocrit	51.3%	<50%	—	Watch for polycythemia

Note: 2.5 year gap since last NBH labs (Oct 2023). This is the longest gap in the dataset. Metformin, CGM, and lifestyle changes since then should show in these results.